Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 7/20 | 0.53 |
| ▸ | MDM4 | O15151 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30340355 | 1.00 | MDM2 (0.53) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL119483 | 0.86 | MDM4 (0.52) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL12040111 | 0.86 | MDM4 (0.52) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL12982089 | 0.80 | MDM4 (0.47) | MDM2MDM4TP53CASP3 | |
| SCHEMBL25657513 | 0.79 | MDM2 (0.61) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL22444591 | 0.79 | MDM2 (0.61) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL30896037 | 0.79 | MDM2 (0.61) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL30510369 | 0.79 | MDM2 (0.61) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL30340128 | 0.78 | MDM4 (0.49) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL23722974 | 0.78 | MDM2 (0.56) | MDM2MDM4TP53TLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059231-A1 | Protease inhibitors | PROTINHI B.V. (NL) | 2025-02-20 | — | — | US | disclosed |
| WO-2024200819-A1 | PROTEASE INHIBITORS FOR CORONAVIRAL INFECTIONS | PROTINHI B.V. (NL) | 2024-10-03 | — | — | WO | disclosed |
| EP-4408454-A1 | PROTEASE INHIBITORS | Protinhi B.V. (NL) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023052636-A1 | PROTEASE INHIBITORS | PROTINHI B.V. (NL) | 2023-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059231-A1 | Protease inhibitors | PREP, DNPEP, TMPRSS15 | MDM2 1711/4885MDM4 2354/4885TP53 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.